JP2022504936A5 - - Google Patents
Info
- Publication number
- JP2022504936A5 JP2022504936A5 JP2021520556A JP2021520556A JP2022504936A5 JP 2022504936 A5 JP2022504936 A5 JP 2022504936A5 JP 2021520556 A JP2021520556 A JP 2021520556A JP 2021520556 A JP2021520556 A JP 2021520556A JP 2022504936 A5 JP2022504936 A5 JP 2022504936A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746952P | 2018-10-17 | 2018-10-17 | |
| US62/746,952 | 2018-10-17 | ||
| US201962916119P | 2019-10-16 | 2019-10-16 | |
| US62/916,119 | 2019-10-16 | ||
| PCT/US2019/056786 WO2020081848A1 (en) | 2018-10-17 | 2019-10-17 | Protein tyrosine phosphatase inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022504936A JP2022504936A (ja) | 2022-01-13 |
| JPWO2020081848A5 JPWO2020081848A5 (https=) | 2022-10-07 |
| JP2022504936A5 true JP2022504936A5 (https=) | 2022-10-07 |
| JP7449282B2 JP7449282B2 (ja) | 2024-03-13 |
Family
ID=68536896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520556A Active JP7449282B2 (ja) | 2018-10-17 | 2019-10-17 | タンパク質チロシンホスファターゼ阻害薬 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12187721B2 (https=) |
| EP (1) | EP3867238B1 (https=) |
| JP (1) | JP7449282B2 (https=) |
| KR (1) | KR102649419B1 (https=) |
| CN (1) | CN114341124B (https=) |
| AU (1) | AU2019359885B2 (https=) |
| BR (1) | BR112021005733A2 (https=) |
| CA (1) | CA3116561C (https=) |
| CL (1) | CL2021000972A1 (https=) |
| CO (1) | CO2021004966A2 (https=) |
| CR (1) | CR20210189A (https=) |
| CU (1) | CU20210029A7 (https=) |
| CY (1) | CY1126122T1 (https=) |
| DO (1) | DOP2021000070A (https=) |
| EC (1) | ECSP21027049A (https=) |
| ES (1) | ES2947464T3 (https=) |
| HU (1) | HUE062404T2 (https=) |
| IL (1) | IL282179B2 (https=) |
| MA (1) | MA53921A (https=) |
| MX (1) | MX2021004410A (https=) |
| NI (1) | NI202100027A (https=) |
| PE (1) | PE20211465A1 (https=) |
| PH (1) | PH12021550674A1 (https=) |
| PL (1) | PL3867238T3 (https=) |
| SG (1) | SG11202102985YA (https=) |
| WO (1) | WO2020081848A1 (https=) |
| ZA (1) | ZA202101960B (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020201991A1 (en) | 2019-04-02 | 2020-10-08 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
| AU2020354475A1 (en) | 2019-09-24 | 2022-05-05 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| CN115960109B (zh) * | 2021-05-31 | 2024-06-25 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
| CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CA3226206A1 (en) | 2021-07-09 | 2023-01-12 | Kanaph Therapeutics Inc. | Shp2 inhibitor and use thereof |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202346305A (zh) * | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CN116731038B (zh) * | 2022-03-10 | 2025-11-21 | 苏州亚盛药业有限公司 | 含氮杂环化合物及其制备方法和应用 |
| CN114621186A (zh) * | 2022-05-12 | 2022-06-14 | 上海维申医药有限公司 | 作为ras信号通路调控剂的杂环化合物 |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025190395A2 (en) * | 2024-03-14 | 2025-09-18 | Pharmaengine, Inc. | Mta-cooperative prmt5 inhibitor |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2004052371A2 (en) | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| WO2007029847A1 (ja) * | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| JP2011510018A (ja) | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| WO2011032050A2 (en) * | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
| US9096590B2 (en) * | 2010-05-24 | 2015-08-04 | Intellikine Llc | Substituted benzoxazoles as PI3 kinase inhibitors |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| US20120225846A1 (en) | 2011-03-02 | 2012-09-06 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| HK1202333A1 (en) | 2011-11-11 | 2015-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| MX383856B (es) | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| US11529347B2 (en) * | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) * | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| US20210230300A1 (en) | 2018-06-04 | 2021-07-29 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
| WO2020201991A1 (en) | 2019-04-02 | 2020-10-08 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
-
2019
- 2019-10-17 US US17/285,997 patent/US12187721B2/en active Active
- 2019-10-17 IL IL282179A patent/IL282179B2/en unknown
- 2019-10-17 AU AU2019359885A patent/AU2019359885B2/en active Active
- 2019-10-17 CR CR20210189A patent/CR20210189A/es unknown
- 2019-10-17 MA MA053921A patent/MA53921A/fr unknown
- 2019-10-17 KR KR1020217014574A patent/KR102649419B1/ko active Active
- 2019-10-17 SG SG11202102985YA patent/SG11202102985YA/en unknown
- 2019-10-17 CU CU2021000029A patent/CU20210029A7/es unknown
- 2019-10-17 WO PCT/US2019/056786 patent/WO2020081848A1/en not_active Ceased
- 2019-10-17 JP JP2021520556A patent/JP7449282B2/ja active Active
- 2019-10-17 EP EP19801996.0A patent/EP3867238B1/en active Active
- 2019-10-17 CA CA3116561A patent/CA3116561C/en active Active
- 2019-10-17 CN CN201980068343.2A patent/CN114341124B/zh active Active
- 2019-10-17 PL PL19801996.0T patent/PL3867238T3/pl unknown
- 2019-10-17 ES ES19801996T patent/ES2947464T3/es active Active
- 2019-10-17 MX MX2021004410A patent/MX2021004410A/es unknown
- 2019-10-17 BR BR112021005733-1A patent/BR112021005733A2/pt unknown
- 2019-10-17 PE PE2021000527A patent/PE20211465A1/es unknown
- 2019-10-17 HU HUE19801996A patent/HUE062404T2/hu unknown
-
2021
- 2021-03-24 ZA ZA2021/01960A patent/ZA202101960B/en unknown
- 2021-03-25 PH PH12021550674A patent/PH12021550674A1/en unknown
- 2021-04-16 NI NI202100027A patent/NI202100027A/es unknown
- 2021-04-16 CL CL2021000972A patent/CL2021000972A1/es unknown
- 2021-04-16 DO DO2021000070A patent/DOP2021000070A/es unknown
- 2021-04-16 EC ECSENADI202127049A patent/ECSP21027049A/es unknown
- 2021-04-19 CO CONC2021/0004966A patent/CO2021004966A2/es unknown
-
2023
- 2023-08-01 CY CY20231100379T patent/CY1126122T1/el unknown
-
2024
- 2024-11-13 US US18/946,138 patent/US20250066357A1/en active Pending